Concizumab

Phase 3Active

0 watching 0 views this week📈 Rising

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Haemophilia A and B With and Without Inhibitors

Conditions

Haemophilia A and B With and Without Inhibitors

Trial Timeline

Mar 24, 2022 → Nov 2, 2029

NCT ID

NCT05135559

About Concizumab

Concizumab is a phase 3 stage product being developed by Novo Nordisk for Haemophilia A and B With and Without Inhibitors. The current trial status is active. This product is registered under clinical trial identifier NCT05135559. Target conditions include Haemophilia A and B With and Without Inhibitors.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (6)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04921956	Pre-clinical	Active	—	—	Congenital Haemophilia
NCT06831734	Pre-clinical	Recruiting	May 2, 2025	Jan 31, 2031	Haemophilia A, Haemophilia B
NCT06285071	Pre-clinical	Recruiting	Aug 8, 2024	Apr 30, 2030	Haemophilia A
NCT05135559	Phase 3	Active	Mar 24, 2022	Nov 2, 2029	Haemophilia A and B With and Without Inhibitors
NCT04082429	Phase 3	Active	Nov 13, 2019	Feb 21, 2028	Haemophilia A Without Inhibitors
NCT04083781	Phase 3	Active	Oct 21, 2019	Feb 21, 2027	Haemophilia A With Inhibitors

Competing Products

20 competing products in Haemophilia A and B With and Without Inhibitors

See all competitors

Product	Company	Stage	Hype Score
Mim8	Novo Nordisk	Phase 3	76
Turoctocog alfa	Novo Nordisk	Phase 3	76
NNC0365-3769 (Mim8)	Novo Nordisk	Phase 3	76
Turoctocog alfa pegol	Novo Nordisk	Pre-clinical	22
Mim8 B, 10 mg/mL + Mim8 B, 100 mg/mL + Mim8 B, placebo	Novo Nordisk	Phase 1	32
Turoctocog alfa pegol	Novo Nordisk	Pre-clinical	22
Concizumab	Novo Nordisk	Phase 3	76
Concizumab	Novo Nordisk	Phase 3	76
turoctocog alfa pegol (N8-GP)	Novo Nordisk	Phase 3	76
Esperoct	Novo Nordisk	Pre-clinical	22
NNC0442-0344 A	Novo Nordisk	Phase 1	32
NNC0365-3769 (Mim8) PPX	Novo Nordisk	Phase 3	76
Concizumab	Novo Nordisk	Pre-clinical	22
Refixia®	Novo Nordisk	Pre-clinical	22
NNC0442-0344 A + Placebo	Novo Nordisk	Phase 1	32
Mim8	Novo Nordisk	Phase 3	76
Turoctocog alfa pegol (N8-GP)	Novo Nordisk	Pre-clinical	22
Nonacog beta pegol	Novo Nordisk	Pre-clinical	22
Concizumab	Novo Nordisk	Pre-clinical	22
Turoctocog alfa	Novo Nordisk	Pre-clinical	22

Other Products from Novo Nordisk

Liraglutide 3.0mg + Placebo Oral Tablet + Phentermine 15 MGApproved

Liraglutide + SalineApproved

Hydrocortisone + PlaceboApproved

biphasic insulin aspart + insulin aspartApproved

Semaglutide, 1.34 mg/mL + Empagliflozin 25 MGApproved